Primary Peritoneal Carcinoma

Primary peritoneal carcinoma (PPC) is a cancer that begins in the peritoneum, the thin tissue lining the abdominal cavity and covering the abdominal organs. It is a carcinoma, meaning it arises from epithelial-type cells, and it closely resembles ovarian and fallopian tube cancers under the microscope. Although it grows in the same body cavity as peritoneal mesothelioma, it is a biologically different disease that originates from different cells.

Origin

The term combines "primary" (originating in that site rather than spreading from elsewhere), "peritoneal" (from the Greek peritonaion, the membrane stretched around the abdominal organs), and "carcinoma" (from the Greek karkinos, meaning crab, used by Hippocrates to describe tumors). PPC was formally recognized as a distinct clinical entity in the 1950s–1970s as pathologists distinguished it from ovarian cancer that had spread to the peritoneum.

Significance in Asbestos Context

PPC is important in asbestos cases primarily because it can be confused with peritoneal mesothelioma, the asbestos-related cancer of the same lining. The two diseases look similar on imaging and at surgery (both produce abdominal swelling, ascites, and tumor nodules studding the peritoneum), but they require different pathology workups, carry different prognoses, and have very different legal implications. An accurate diagnosis distinguishing PPC from mesothelioma typically requires immunohistochemical staining (markers such as calretinin, WT-1, BAP1, PAX8, and BerEP4) and sometimes electron microscopy. Misdiagnosis runs in both directions: a person with peritoneal mesothelioma may initially be told they have PPC or ovarian-type cancer, delaying recognition of an asbestos-caused disease and the legal claims that flow from it. Patients and families should make sure the pathology has been reviewed by someone experienced with mesothelial tumors before accepting a diagnosis of PPC.

Example Sentence

After her initial diagnosis of primary peritoneal carcinoma, a second pathology review at a mesothelioma specialty center reclassified the tumor as epithelioid peritoneal mesothelioma, which changed both her treatment plan and her legal options.

Related Terms

Peritoneal Mesothelioma, Immunohistochemistry, Calretinin, BAP1, Ascites, Differential Diagnosis

Notes

• If you have been told you have primary peritoneal carcinoma, ask whether mesothelioma-specific markers (calretinin, WT-1, BAP1, D2-40) were included in the immunohistochemistry panel; if not, request a second opinion from a mesothelioma program before starting treatment.
• Preserve all pathology slides, blocks, and reports. These can be sent out for expert review and are critical evidence if the diagnosis is later revised to mesothelioma.
• Document any history of asbestos exposure (occupational, household, or environmental) in writing and share it with your oncologist; this can influence how aggressively a mesothelial origin is investigated.
• Centers with experience in peritoneal surface malignancies (often offering cytoreductive surgery with HIPEC) routinely see both PPC and peritoneal mesothelioma and can help clarify an uncertain diagnosis.